Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
2.100
+0.020 (0.96%)
At close: Jan 16, 2026, 4:00 PM EST
2.100
0.00 (0.00%)
After-hours: Jan 16, 2026, 4:10 PM EST
Opus Genetics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Opus Genetics stock have a consensus rating of "Strong Buy" and an average price target of $7.43, which forecasts a 253.81% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $9.00.
Price Target: $7.43 (+253.81%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 10, 2025.
Analyst Ratings
The average analyst rating for Opus Genetics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 4 | 5 | 5 |
| Buy | 0 | 0 | 1 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 5 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +328.57% | Dec 10, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $7 | Buy | Initiates | $7 | +233.33% | Nov 25, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +328.57% | Nov 13, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +328.57% | Nov 7, 2025 |
| Wedbush | Wedbush | Buy Initiates $8 | Buy | Initiates | $8 | +280.95% | Oct 29, 2025 |
Financial Forecast
Revenue This Year
13.49M
from 10.99M
Increased by 22.70%
Revenue Next Year
18.07M
from 13.49M
Increased by 33.96%
EPS This Year
-0.69
from -2.15
EPS Next Year
-0.42
from -0.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 16.0M | 31.5M | ||||
| Avg | 13.5M | 18.1M | ||||
| Low | 11.1M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 45.9% | 133.6% | ||||
| Avg | 22.7% | 34.0% | ||||
| Low | 0.7% | -27.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.56 | -0.30 | ||||
| Avg | -0.69 | -0.42 | ||||
| Low | -0.79 | -0.56 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.